Taking on-board the Alexion acquisition
21/07/21 -"AstraZeneca has completed the acquisition of Alexion Pharmaceuticals (US rare diseases specialist). Given that rare diseases are a high-growth and attractive margin area (even ahead of oncology), ..."
Pages
64
Language
English
Published on
21/07/21
You may also be interested by these reports :
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...
08/06/26
Anticipated sales are now even more skewed toward 2H, with HSD growth expected in 1H. We also record a CHF15m decrease in Building K sales in 2026, ...